Holen Sie sich die Stockscreener-App
2.55
9.89%
-0.28
Handel nachbörslich:
2.55
Schlusskurs vom Vortag:
$2.83
Offen:
$2.73
24-Stunden-Volumen:
358.89K
Relative Volume:
0.80
Marktkapitalisierung:
$137.65M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-1.6139
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-17.48%
1M Leistung:
-21.30%
6M Leistung:
-30.42%
1J Leistung:
-72.07%
1-Tages-Spanne:
$2.54
$2.81
1-Wochen-Bereich:
$2.54
$3.13
52-Wochen-Spanne:
$2.54
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
2.55 | 137.65M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India
Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire
Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India
Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationFULC - ACCESS Newswire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Fulcrum Therapeutics Ends Agreement with MyoKardia By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Ends Agreement with MyoKardia - Investing.com India
Fulcrum Therapeutics Faces Termination of Key Agreement - TipRanks
Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co - Marketscreener.com
Will Fulcrum Therapeutics Reveal New Rare Disease Pipeline Updates at Upcoming Leerink Conference? - StockTitan
Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Issues Negative Forecast for FULC Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of FULC Q1 Earnings - Defense World
Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright - Defense World
Fulcrum Therapeutics' (FULC) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
What is HC Wainwright's Forecast for FULC FY2029 Earnings? - MarketBeat
FY2029 Earnings Estimate for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Hold” from Brokerages - Defense World
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains - TipRanks
Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Shareholders that lost money on Fulcrum Therapeutics, Inc. (FULC) should contact Levi & Korsinsky about Securities Fraud InvestigationFULC - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC investor five-year losses grow to 82% as the stock sheds US$28m this past week - Simply Wall St
Lost Money on Fulcrum Therapeutics, Inc.(FULC)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result - Yahoo Finance
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum (FULC) Issues Strategic Employee Stock Options PackageKey Details Revealed - StockTitan
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):